CoChat

Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques

Zannad, Faiez, De Backer, Guy, Graham, Ian, Lorenz, Matthias, Mancia, Giuseppe, Morrow, David A., Reiner, Željko, Koenig, Wolfgang, Dallongeville, Jean, Macfadyen, Robert J., Ruilope, Luis M., Wilhelmsen, Lars, the ESC Working Group on CardioVascular Pharmacology and Drug Therapy · 2012 · Fundamental & Clinical Pharmacology
Cited by 46

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

The aim of this paper is to review and discuss current methods of risk stratification for cardiovascular disease (CVD) prevention, emerging biomarkers, and imaging techniques, and their relative merits and limitations. This report is based on discussions that took place among experts in the area during a special CardioVascular Clinical Trialists workshop organized by the European Society of Cardiology Working Group on Cardiovascular Pharmacology and Drug Therapy in September 2009. Classical risk factors such as blood pressure and low‐density lipoprotein cholesterol levels remain the cornerstone of risk estimation in primary prevention but their use as a guide to management is limited by several factors: (i) thresholds for drug treatment vary with the available evidence for cost‐effectiveness and benefit‐to‐risk ratios; (ii) assessment may be imprecise; (iii) residual risk may remain, even with effective control of dyslipidemia and hypertension. Novel measures include C‐reactive protein, lipoprotein‐associated phospholipase A 2, genetic markers, and markers of subclinical organ damage, for which there are varying levels of evidence. High‐resolution ultrasound and magnetic resonance imaging to assess carotid atherosclerotic lesions have potential but require further validation, standardization, and proof of clinical usefulness in the general population. In conclusion, classical risk scoring systems are available and inexpensive but have a number of limitations. Novel risk markers and imaging techniques may have a place in drug development and clinical trial design. However, their additional value above and beyond classical risk factors has yet to be determined for risk‐guided therapy in CVD prevention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1472-8206.2011.01023.x

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 46

Metadata

Authors
Zannad, F., De Backer, G., Graham, I., Lorenz, M., Mancia, G., Morrow, D. A., Reiner, Ž., Koenig, W., Dallongeville, J., Macfadyen, R. J., Ruilope, L. M., Wilhelmsen, L., & the ESC Working Group on CardioVascular Pharmacology and Drug Therapy
Venue
Fundamental & Clinical Pharmacology
Publisher
Wiley
Published
2012-01-05
Volume
26
Issue
2
Pages
163-174
ISSN
  • 0767-3981 (ISSN-L)
  • 1472-8206
OpenAlex
W1924419006
Cited by
46
References
20
FWCI
5.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques. https://app.cochat.ai/papers/10.1111/j.1472-8206.2011.01023.x
The paper
Zannad, F., De Backer, G., Graham, I., Lorenz, M., Mancia, G., Morrow, D. A., Reiner, Ž., Koenig, W., Dallongeville, J., Macfadyen, R. J., Ruilope, L. M., Wilhelmsen, L., & the ESC Working Group on CardioVascular Pharmacology and Drug Therapy. (2012). Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/j.1472-8206.2011.01023.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.